QSV Gets Tissue Therapies Contract

QSV Biologics, Ltd. has signed a contract with biomedical company, Tissue Therapies, Ltd., for the process development and cGMP manufacture of clinical quantities of some of the therapeutic protein components of the VitroGro platform for the accelerated healing of burns. These are some of the essential components of the VitroGro, formulation that Tissue Therapies will use in a clinical trial later this year. Tissue Therapies is an Australian company developing biomedical technologies for wound healing, tissue regeneration and various cell culture applications.

Under the agreement, QSV will be responsible for technology transfer, process development, scaling-up and cGMP production in QSV’s manufacturing facility in Edmonton, Alberta. Terms of the final contract have not been disclosed.

Dr. Graeme Macaloney, QSV founder and chief executive officer, said, “We are extremely pleased to be selected by Tissue Therapies to be their GMP manufacturer of choice for these components. The Tissue Therapies’ management and technical team represent a top-notch international organization developing a valuable therapeutic breakthrough for the treatment of burns and related conditions. Working with an Australian-based biopharmaceutical company represents a milestone for QSV in extending our global presence and underscores the benefit of the Health Canada Mutual Recognition Agreement with Australia and other jurisdictions like the EU.”

Dr. Steven Mercer, Tissue Therapies’ chief executive officer, said, “We are very happy to have established a commercial relationship with QSV for the supply of essential GMP components for our VitroGro products. This agreement was the result of a careful international assessment of potential suppliers, with selection criteria including cGMP, technical and scientific experience, quality of production facilities and international health regulatory expertise. QSV impressed us in all these areas, particularly with their professionalism and scientific and regulatory expertise. We look forward to a long term, mutually beneficial relationship.”